Clinical trial
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic…
NCT00372944 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00372944 |
|---|---|
| Title | AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy |
| Official title | A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | AZD6244, capecitabine |
| Enrollment | 70 |
| Start date | Aug 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 7, 2006 |
| Last update posted | Aug 13, 2014 |
| Countries | Australia, Bulgaria, Hungary, Romania, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: